Neoadjuvant Systemic Therapy in Early Breast Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: closed (10 March 2021) | Viewed by 40473
Special Issue Editors
Interests: inflammatory breast cancer (IBC); breast cancer predictive factors; neoadjuvant endocrine therapy; hormone-receptor-positive/HER2-negative metastatic breast cancer.
Special Issue Information
Dear Colleagues,
The concept of neoadjuvant systemic treatments (NSTs) in early breast cancer (EBC) has evolved over the past two decades.
Initially proposed for tumor downstaging only, this strategy is now used to study sensitivity to treatments in vivo. Neoadjuvant clinical trials, either with endocrine therapy (ET) or chemotherapy (CT)-based +/- targeted therapies, have recapitulated the results of their counterpart adjuvant trials but with fewer patients and faster, since NST endpoints, notably the pathological response, are obtained in a few months. Indeed, the residual cancer burden has prognostic value. Achievement of a pathological complete response (pCR) after NST correlates with survival in aggressive EBC subtypes, namely triple-negative and HER2-positive, particularly in those who are HR-negative. The neoadjuvant strategy also provides us with a unique opportunity to assess the value of predictive biomarkers and to monitor response using functional/molecular imaging.
More recently, NST has been used for drug development in two ways: first, in adaptative clinical trials that investigate serial drugs in specific BC subtypes; second, in the development of adjuvant trials for those patients not obtaining a pCR to NST. NST is now recommended for aggressive EBC molecular subtypes almost irrespective of the tumor size.
Before NST becomes routine in EBC, we need to determine how best to monitor response, how best to improve IBC outcome, the place of CT/ET in HR+/HER2- BC, and how best to downstage surgery. This Special Issue of Cancers aims to present a collection of original research articles and reviews that address these, and related, issues in Neoadjuvant Systemic Therapy in Early Breast Cancer.
Dr. Florence Lerebours
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- predictive biomarkers
- functional imaging
- breast cancer molecular subtypes
- pathological response
- post neoadjuvant treatments
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.